BALCHEM CORP(BCPC)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
BALCHEM CORP (BCPC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCPC at 64.5/100 on a 32-signal composite quality model, placing it at rank #539 of 2,962 stocks — the top 25% of the AI-ranked universe. BCPC scores in the top quartile across balance sheet strength (84.9). Shareholder dilution risk is elevated at 42.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BALCHEM CORP reports quarterly revenue of $284.0M, net income of $44.6M, an operating margin of 20.8%. Top institutional holders of BCPC by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BCPC trades on the Nasdaq exchange and files with the SEC under CIK 9326. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BALCHEM CORP directly from SEC EDGAR.
AI Quality Score
64.5/100
AI Rank
#539
Revenue
$284.0M
Net Income
$44.6M
Operating Margin
20.8%
BCPC key financials by period
BALCHEM CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.0B
$154.8M
20.2%
FY 2024
10-K
$953.7M
$128.5M
19.2%
FY 2023
10-K
$922.4M
$108.5M
17.3%
FY 2022
10-K
$942.4M
$105.4M
15.4%
FY 2021
10-K
$799.0M
$96.1M
16.0%
FY 2020
10-K
$703.6M
$84.6M
15.8%
Institutions holding BCPC
Institutional investors reporting a position in BALCHEM CORP on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Balchem grew Q2 net sales 11.2% YoY to $284.0M, with earnings from operations up 15.1% to $59.2M as all three segments posted higher volume, mix, and pricing.
Biggest Revenue Drivers
Human Nutrition & Health$176.9M+10.0% YoY
Driven by higher sales in both the nutrients business and the food ingredients and solutions businesses
Animal Nutrition & Health$64.5M+15.0% YoY
Driven by higher sales in both the monogastric and ruminant species markets
Biggest Revenue Drivers
Total revenue: $284.0M+11.2% YoY
Human Nutrition & Health$176.9M+10.0% YoY
Driven by higher sales in both the nutrients business and the food ingredients and solutions businesses
Animal Nutrition & Health$64.5M+15.0% YoY
Driven by higher sales in both the monogastric and ruminant species markets
Specialty Products$40.5M+8.9% YoY
Due to higher sales in both the performance gases and plant nutrition businesses
Other and Unallocated$2.1M+44.4% YoY
Largest Expense Items
Cost of sales$180.3M+11.1% YoY
Rose with sales growth, partially offset by manufacturing efficiencies
Selling expenses$21.1M+9.5% YoY
General and administrative expenses$18.8M+4.0% YoY
Operating expense growth overall was primarily due to higher compensation-related costs of $2,942K
Research and development expenses$4.5M+5.4% YoY
Margins: Gross margin rose to 36.5% of net sales from 36.4%, on sales growth and manufacturing efficiencies partially offset by higher manufacturing input costs; operating margin improved to 20.9% from 20.1%.
Watch Items from the Filing
Company entered Amendment No. 1 to its credit agreement on July 24, 2026, raising the revolver from $550M to $650M and extending maturity to 2031, used to repay the $152M outstanding balance.
U.S. Supreme Court invalidated certain IEEPA tariffs in February 2026, followed by new tariffs under other authorities; Balchem says it cannot yet estimate the total financial impact.
Company continues remediation and investigation activity at its Verona, Missouri Superfund site (dioxin contamination) and settled EPA/DOJ Clean Air Act allegations in January 2025 for a $300K penalty plus $350K community spending.
Effective tax rate rose to 22.8% from 21.9% YoY, primarily due to lower tax benefits from stock-based compensation.
Company repatriated $23,460K from its Belgium subsidiary during Q2 2026 to pay down U.S. debt, out of $53,925K total cash held by foreign subsidiaries.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
